226 related articles for article (PubMed ID: 24021750)
1. Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science.
Sahin IH; Hassan MM; Garrett CR
Cancer Lett; 2014 Apr; 345(2):249-57. PubMed ID: 24021750
[TBL] [Abstract][Full Text] [Related]
2. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action.
Husain SS; Szabo IL; Tamawski AS
Am J Gastroenterol; 2002 Mar; 97(3):542-53. PubMed ID: 11922545
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs.
Shaheen NJ; Straus WL; Sandler RS
Cancer; 2002 Feb; 94(4):950-63. PubMed ID: 11920463
[TBL] [Abstract][Full Text] [Related]
4. Changes in gene expression contribute to cancer prevention by COX inhibitors.
Baek SJ; Eling TE
Prog Lipid Res; 2006 Jan; 45(1):1-16. PubMed ID: 16337272
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention.
Fajardo AM; Piazza GA
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(2):G59-70. PubMed ID: 26021807
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Grösch S; Maier TJ; Schiffmann S; Geisslinger G
J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.
Wang R; Guo L; Wang P; Yang W; Lu Y; Huang Z; Tang C
Curr Pharm Des; 2013; 19(1):115-25. PubMed ID: 22950494
[TBL] [Abstract][Full Text] [Related]
8. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
Farrow DC; Vaughan TL; Hansten PD; Stanford JL; Risch HA; Gammon MD; Chow WH; Dubrow R; Ahsan H; Mayne ST; Schoenberg JB; West AB; Rotterdam H; Fraumeni JF; Blot WJ
Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):97-102. PubMed ID: 9488582
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Jiménez P; García A; Santander S; Piazuelo E
Curr Pharm Des; 2007; 13(22):2261-73. PubMed ID: 17691999
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives.
Dermond O; Rüegg C
Drug Resist Updat; 2001 Oct; 4(5):314-21. PubMed ID: 11991685
[TBL] [Abstract][Full Text] [Related]
11. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.
Wu WK; Sung JJ; Lee CW; Yu J; Cho CH
Cancer Lett; 2010 Sep; 295(1):7-16. PubMed ID: 20381235
[TBL] [Abstract][Full Text] [Related]
13. [Non-steroidal anti-inflammatory drugs and chemoprevention of digestive cancer].
Wei WQ; Qiao YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Feb; 23(1):78-82. PubMed ID: 12905826
[TBL] [Abstract][Full Text] [Related]
14. A COX-2-specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAIDs' GI toxicity?
Cryer B
Am J Gastroenterol; 2006 Apr; 101(4):711-3. PubMed ID: 16635218
[TBL] [Abstract][Full Text] [Related]
15. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer.
Rahme E; Ghosn J; Dasgupta K; Rajan R; Hudson M
BMC Cancer; 2005 Dec; 5():159. PubMed ID: 16343343
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors.
Reddy BS; Rao CV
J Environ Pathol Toxicol Oncol; 2002; 21(2):155-64. PubMed ID: 12086402
[TBL] [Abstract][Full Text] [Related]
17. Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer.
Hahn E; Kraus S; Arber N
Dig Dis; 2010; 28(4-5):585-9. PubMed ID: 21088406
[TBL] [Abstract][Full Text] [Related]
18. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
19. Postoperative non-steroidal anti-inflammatory drugs and colorectal anastomotic leakage. NSAIDs and anastomotic leakage.
Klein M
Dan Med J; 2012 Mar; 59(3):B4420. PubMed ID: 22381097
[TBL] [Abstract][Full Text] [Related]
20. Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
Luk GD
Schweiz Med Wochenschr; 1996 May; 126(19):801-12. PubMed ID: 8693304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
